Reuters
One day before a Food and Drug Administration
(news - web sites) panel begins discussing the future of such drugs, the New England Journal of Medicine (news - web sites) published details of three studies stopped early because patients taking the drugs were having more heart attacks, strokes and other adverse events than patients not taking them.
"I think we are at risk of losing the class of drugs," said Dr. Robert Bresalier of the University of Texas M.D. Anderson Cancer Center, who was studying one of the drugs, Vioxx, known generically as rofecoxib, in a colon cancer trial.
More...
|
